Co‑Diagnostics priced a $7 million direct offering to institutional investors to fund working capital and corporate purposes, and the company also established a joint venture with Arabian Eagle Manufacturing to manufacture and distribute its molecular diagnostics products across Saudi Arabia and 18 other MENA countries. The financing and commercial expansion aim to support rollout of Co‑Dx’s point‑of‑care molecular systems and assay portfolio in the Middle East and North Africa, leveraging local manufacturing and distribution to address regional testing needs. Maxim Group acted as placement agent for the offering. For diagnostics developers, the moves illustrate a dual approach — immediate liquidity via capital markets and targeted regional partnerships to scale manufacturing and access in growth geographies.